TNFSF10 and malignant colon neoplasm: Unfortunately, its clinical utility has been limited due to multiple mechanisms of TRAIL resistance.18,19 Colon cancer is a leading cause of cancer-related mortality for which targeted therapy is critically needed; however, clinical trials using TRAIL monotherapy have shown no response in these patients, and we similarly have demonstrated TRAIL resistance in the majority of human colon cancer cell lines tested.